Literature DB >> 8018559

Colon carcinoma cells switch their response to transforming growth factor beta 1 with tumor progression.

S Hsu1, F Huang, M Hafez, S Winawer, E Friedman.   

Abstract

Transforming growth factor beta 1 (TGF-beta 1) switches from an inhibitor of tumor cell growth to a stimulator of growth and invasion during human colon carcinoma progression. We originally observed that metastatic colon carcinoma cells in primary culture responded to TGF-beta 1 by proliferation, whereas moderate to well-differentiated primary site colon carcinomas were growth inhibited by TGF-beta 1 (P. Schroy et al., Cancer Res., 50: 261-265, 1990). We then cloned several colon carcinoma cell lines which modeled these responses to TGF-beta 1 and expressed TGF-beta 1 (M. M. Hafez et al., Cell Growth & Differ., 1: 617-626, 1990; 3: 753-762, 1992). Two of these colon carcinoma cell lines, U9 and HD3, which activate approximately equal amounts of TGF-beta 1 and express equal amounts of TGF-beta receptors, are now used to compare the effects of TGF-beta 1 in modulating invasive behavior. The U9 cell line exhibits autocrine-positive growth regulation in vitro by TGF-beta 1, whereas the HD3 cell line shows the opposite response, autocrine-negative regulation. Blocking endogenous TGF-beta 1 with isotype-specific antibody inhibited U9 cell growth because autocrine TGF-beta 1 acts as a mitogen for U9 cells. In contrast, antibody to TGF-beta 1 stimulated HD3 cell proliferation because autocrine TGF-beta 1 inhibits growth of these cells. U9 cells were 13-fold more invasive in vitro through a collagen I layer than HD3 cells.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8018559

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  19 in total

1.  Relation between transforming growth factor-β1 expression, its receptor and clinicopathological factors and survival in HER2-negative gastric cancers.

Authors:  Julian Ananiev; Maya Gulubova; Georgi Tchernev; Mariana Penkova; Radostina Miteva; Alexander Julianov; Irena Manolova
Journal:  Wien Klin Wochenschr       Date:  2011-10-24       Impact factor: 1.704

2.  Loss of p12CDK2-AP1 expression in human oral squamous cell carcinoma with disrupted transforming growth factor-beta-Smad signaling pathway.

Authors:  Hui Peng; Satoru Shintani; Yong Kim; David T Wong
Journal:  Neoplasia       Date:  2006-12       Impact factor: 5.715

3.  Targeted deletion of Smad4 shows it is required for transforming growth factor beta and activin signaling in colorectal cancer cells.

Authors:  S Zhou; P Buckhaults; L Zawel; F Bunz; G Riggins; J L Dai; S E Kern; K W Kinzler; B Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

4.  Using positron emission tomography with [(18)F]FDG to predict tumor behavior in experimental colorectal cancer.

Authors:  B M Burt; J L Humm; D A Kooby; O D Squire; S Mastorides; S M Larson; Y Fong
Journal:  Neoplasia       Date:  2001 May-Jun       Impact factor: 5.715

5.  Abrogation of TGFbeta signaling induces apoptosis through the modulation of MAP kinase pathways in breast cancer cells.

Authors:  Xiufen Lei; Junhua Yang; Robert W Nichols; L-Z Sun
Journal:  Exp Cell Res       Date:  2007-02-28       Impact factor: 3.905

6.  Type III TGF-β receptor enhances colon cancer cell migration and anchorage-independent growth.

Authors:  Catherine E Gatza; Alisha Holtzhausen; Kellye C Kirkbride; Allyson Morton; Michael L Gatza; Michael B Datto; Gerard C Blobe
Journal:  Neoplasia       Date:  2011-08       Impact factor: 5.715

7.  TGF-β regulation of gene expression at early and late stages of HPV16-mediated transformation of human keratinocytes.

Authors:  Sangeeta Kowli; Rupa Velidandla; Kim E Creek; Lucia Pirisi
Journal:  Virology       Date:  2013-09-19       Impact factor: 3.616

8.  Transforming growth factor beta can be a parameter of aggressiveness of pT1 colorectal cancer.

Authors:  Katarzyna Guzinska-Ustymowicz; Andrzej Kemona
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

9.  Autocrine growth inhibition by transforming growth factor beta-1 (TGFbeta-1) in human neuroendocrine tumour cells.

Authors:  A Wimmel; B Wiedenmann; S Rosewicz
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

10.  Physical and biological characterization of a growth-inhibitory activity purified from the neuroepithelioma cell line A673.

Authors:  K Stam; A A Stewart; G Y Qu; K K Iwata; D Fenyö; B T Chait; D R Marshak; J D Haley
Journal:  Biochem J       Date:  1995-01-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.